ACT Brief: Data Pipeline Fragmentation, Vaccine Trial Pressures, and BTK Degrader Partnership

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new interview, Raj Indupuri, CEO and co-founder of eClinical Solutions, explained how the FDA's push toward continuous data review is exposing fundamental fragmentation in clinical trial infrastructure. Unified data pipelines capable of integrating disparate systems in real time are essential to make regulatory continuous monitoring operationally feasible.
• In a new FAQ, vaccine trials face mounting pressure from rising costs ($60-$148 million Phase III), regulatory uncertainty around immunobridging and approval pathways, and persistent vaccine hesitancy. Portfolio-level standardization of endpoints and eCOA instruments can reduce build times 50%, while behavioral science frameworks—measuring participant psychology rather than just visits—are critical for managing engagement in mega trials.
• Roche and Nurix entered a $2.3 billion global collaboration on a BTK degrader designed to overcome resistance mutations and incomplete pathway suppression that limit conventional BTK inhibitors. Phase III trials in CLL are planned for summer 2026, with potential expansion to immunology and neurology indications where BTK signaling plays a central role.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.